Methods of treatment of acute renal failure

Details Methods of treatment of acute renal failure Methods of treatment of acute renal failure

2007-07-10

2010-11-30

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024500

Reexamination Certificate

active

07842674

ABSTRACT:
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

REFERENCES:
patent: 4497817 (1985-02-01), Murase et al.
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6593353 (2003-07-01), Gudkov et al.
patent: 6982277 (2006-01-01), Gudkov et al.
patent: 7008956 (2006-03-01), Gudkov et al.
patent: 7012087 (2006-03-01), Gudkov et al.
patent: 2002/0019425 (2002-02-01), Gudkov et al.
patent: 2004/0014956 (2004-01-01), Woolf et al.
patent: 2004/0180351 (2004-09-01), Giese et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0069056 (2006-03-01), Feinstein et al.
patent: 2006/0021739 (2006-09-01), Feinstein
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0185047 (2007-08-01), Bhat et al.
patent: 2010/0048425 (2010-02-01), Khvorova et al.
patent: 0430334 (1991-06-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2006/035434 (2006-04-01), None
Barik, Sailen (2005). “Silence of the Transcripts; RNA Interference In Medicine,” J. Mol. Med. 83:764-773.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses By Nasally Administered siRNA,” Nature Medicine, 11(1):50-55.
Lee, Youngtae et al., (2003). “The nuclear RNase III Drosha initiates mircoRNA processing,” Nature, 425:415-419.
Wang, J. et al., (2003). “A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against . . . ,” The J. of Neuroscience, 23(24):8596-8607.
Zhang, M. et al., (2003). “Pifithrin-α Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis,” Neuroscience, 120:191-205.
Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.
Pending claims in Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.
Andrei Gudkov et al., U.S. Appl. No. 11/136,231, filed May 24, 2005.
International Search Report issued by the International Searching Authority (ISA/US) on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.
Written Opinion of the International Searching Authority (ISA/US) issued on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.
Office Action issued on Mar. 23, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.
Office Action issued on Jul. 2, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.
Office Action issued on Dec. 28, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Jun. 6, 2002 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.
Office Action issued on Feb. 12, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.
Office Action issued on Mar. 26, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Jul. 15, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Oct. 9, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.
Office Action issued on Nov. 19, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Apr. 6, 2004 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.
Office Action issued on Jul. 9, 2004 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.
Office Action issued on Jul. 13, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Nov. 26, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.
Office Action issued on Sep. 9, 2004 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.
Office Action issued on Jan. 3, 2005 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.
Office Action issued on Apr. 21, 2005 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.
Office Action issued on Oct. 30, 2007 in connection with U.S. Appl. No. 11/136,231, filed May 24, 2005.
Communication under Rule 112 EPC issued by the European Patent Office on Dec. 16, 2003 in connection with European Patent Application No. 00914455.1.
Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Feb. 12, 2004 in connection with European Patent Application No. 00914455.1.
Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Aug. 19, 2004 in connection with European Patent Application No. 00914455.1.
Communication pursuant to Article 96(2)EPC issued by the European Patent Office on May 13, 2005 in connection with European Patent Application No. 00914455.1.
Result of consultation issued by the European Patent Office on Oct. 25, 2005 in connection with European Patent Application No. 00914455.1.
Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Mar. 10, 2006 in connection with European Patent Application No. 00914455.1.
Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Oct. 24, 2006 in connection with European Patent Application No. 00914455.1.
Pending claims in U.S. Appl. No. 11/136,231, filed May 24, 2005.
Final Office Action issued on Dec. 3, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.
Bartel, D.P., (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116:281-297.
Bernstein, E., et al., (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.
Botchkarev, V.A., et al., (2000) p53 Is Essential for Chemotherapy-induced Hair Loss. Cancer Res. 60:5002-5006.
Brummelkamp, T.R., et al., (2002) A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. Science 296:550-553.
Caplen, N.J., et al., (2001) Specific inhibition of gene expression by small-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98(17):9742-9747.
Chalk, A.M., et al., (2004) Improved and automated prediction of effective siRNA. Biochem. Biophys. Res. Commun. 319:264-274.
Chernov, M.V. and Stark, G.R., (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14:2503-2510.
Cotsarelis, G. and Millar, S.E., (2001) Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7(7):293-301.
Elbashir, S.M., et al., (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200.
Elbashir, S.M., et al., (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
Fire, A., et al., (1998) Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans. Nature 391:806-811.
Gottlieb, T.M., et al., (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.
Komarov, P.G., et al., (1999) A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science 285:1733-1737.
Komarova, E.A., et al., (1997) Transgenic mice

Affiliated with

Also associated with

Rating

Methods of treatment of acute renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment of acute renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of acute renal failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4242515